Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4 Becker’s contributions to the campaign, meanwhile, include Type 2 diabetes-friendly twists on recipes ...

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

But what if Novo Nordisk could market a therapy that's even more effective than these two? Enter CagriSema, an investigational diabetes and obesity medicine the company is testing in phase 3 studies.

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

The Food and Drug Administration on Tuesday approved Novo Nordisk's Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular ...

and now it looks like we'll have the next generation of these breakthrough weight loss and diabetes medicines on shelves by early next year. Less than five years on from when Novo Nordisk's ...

While Novo Nordisk has established a strong position in metabolic disease with the GLP-1 agonist semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for obesity, the pharmaceutical ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Shares of Novo Nordisk slipped ... overweight or obesity and type 2 diabetes," said Martin Holst Lange, executive vice president for development at Novo Nordisk. "We look forward to bringing ...